ReviewDrug design, development and therapy2026
Exploring Chinese Herbal Medicines for Acute Kidney Injury: Pharmacological Mechanisms and Clinical Potential.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Crocins ameliorate acute kidney injury in glycerol-induced rhabdomyolysis by targeting the PLIN1/PPARs signaling pathway.Frontiers in pharmacology · 2026Article
- Molecular immunopharmacology of traditional Chinese medicine-derived compounds in membranous nephropathy: mechanistic insights into immune aging and kidney essence deficiency.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute kidney injury (AKI) is a serious clinical condition marked by a rapid decline in renal function, leading to high morbidity, mortality, and healthcare burden. Despite advances in supportive care, effective pharmacologic therapies remain lacking, prompting interest in alternative approaches, including Chinese herbal medicines (CHMs). Purpose: This review summarizes recent experimental and clinical research on CHMs for AKI, highlighting mechanisms of action, translational challenges, and future directions. Methods: A narrative review was conducted using PubMed, Web of Science, Google Scholar, and ClinicalTrials.gov through May 2025, with search terms including "acute kidney injury", "Chinese herbal medicine", "natural products", and "plant extracts". Both preclinical and clinical studies were included to provide a comprehensive overview. Results: Various CHMs and traditional formulations have demonstrated renal protective effects in AKI through anti-inflammatory, antioxidant, anti-apoptotic, and mitochondrial-protective mechanisms. Key pathways targeted include NF-κB, Nrf2, PI3K/Akt, MAPK, and apoptotic regulators like Bcl-2/Bax and caspases. Notable agents include berberine, baicalin, puerarin, and multi-herb formulas such as QiShenYiQi and Jianpi Yishen Tang, which offer multi-targeted therapeutic potential. Conclusion: CHMs present a promising avenue for AKI treatment by modulating multiple cellular pathways implicated in disease progression. While preclinical studies are encouraging, robust clinical trials and standardization of formulations are critical for validating efficacy and ensuring safety. Integrating CHMs into modern nephrology through evidence-based strategies may enhance therapeutic options for AKI and advance the development of novel, nature-derived treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.